Health Cancer tests - Hope has appeared on the horizon for advanced, low-cost cancer diagnosis in Nigeria and South Africa, courtesy of an exclusive licence agreement between Global Health Management Informatics, GHMI – a Houston-based company focusing on advancing effective and affordable healthcare solutions – and AnalizaDx, a Cleveland-based company developing a pipeline of next-generation cancer diagnostics products.
Under the partnership terms, GHMI in agreement with AnalizaDx is offering its simple blood-based cancer diagnostics and screening tests to enable early and effective treatment while reducing unnecessary procedures
Through its network of collaborations with leading hospitals and clinical laboratories, GHMI will begin offering AnalizaDx's PSA/SIA, a next generation prostate cancer test that has demonstrated superior performance in differentiating between prostate cancer and other benign conditions using blood sample. Follow-on tests will target breast, colon, ovarian, and other cancers.
Dr. Arnon Chait, President of AnalizaDx, said the technology platform provides lab-based solutions that could bring definitive answers to millions using blood-based analysis of protein biomarker structure.
Also speaking, Dr. Debo Awosika-Olumo, President/CEO of GHMI stated: "With operations in the US and Africa, we plan to enable smooth transfer of technology and diagnostics products in the near futuer.
"We are pleased to enter into this ground-breaking agreement to allow us to offer a series of advanced low-cost cancer tests throughout the African continent. We believe this partnership will result in many saved lives, while making good use of precious healthcare resources in both developed and emerging markets in Africa," he said.
The partnership is being extended to other parts of Africa and Islands of The Caribbean.
By Sola Ogundipe